Nobuya Ishii

发表

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.

N. Rosen, T. Sakai, M. Arisawa, 2013, Cancer research.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

S. Lowe, C. Lukacs, N. Rosen, 2014, Cancer cell.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

S. Mu, R. Rueger, P. Goelzer, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical The Safety , Tolerability , Pharmacokinetics , and Pharmacodynamics of Single Oral Doses of CH 4987655 in Healthy Volunteers : Target Suppression Using a Biomarker

S. Mu, R. Rueger, P. Goelzer, 2009 .

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

Hiroshi Sakamoto, H. Sakamoto, T. Fukami, 2011, Cancer cell.

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer

Y. Aoki, O. Kondoh, A. Suda, 2013, Cancer science.

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014, Molecular Cancer Therapeutics.

Small Molecule Therapeutics The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH 5183284 / Debio 1347 , a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014 .

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

N. Yanaihara, A. Okamoto, Tadao Tanaka, 2005, Clinical Cancer Research.

Integration of proteomic analyses to monitor the activity status of phosphorylation signaling.

S. Nagahashi, N. Yabuki, K. Nagano, 2011, Journal of proteomics.

Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer

M. Aoki, N. Ishii, T. Mio, 2018, Molecular Cancer Therapeutics.

Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment

K. Nagano, S. Morimoto, T. Shinkawa, 2009, Proteomics.

A signature-based method for indexing cell cycle phase distribution from microarray profiles

Hideaki Mizuno, Yoshito Nakanishi, Akinori Sarai, 2009, BMC Genomics.

Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

N. Yanaihara, A. Okamoto, Tadao Tanaka, 2007 .

Indoleamine 2 , 3-Dioxygenase Serves as aMarker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

N. Yanaihara, A. Okamoto, Tadao Tanaka, 2005 .

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Li Lu, Michael Pawlak, Jean Tessier, 2014, EJNMMI Research.

YES1 is a targetable oncogene in cancers harboring YES1 gene amplification.

H. Koyano, N. Ishii, Haruhiko Sato, 2019, Cancer research.

Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4

K. Kashima, J. Hata, N. Ishii, 2014, Cancer science.

Establishment and characterization of an androgen receptor‐dependent, androgen‐independent human prostate cancer cell line, LNCaP‐CS10

Ayako Nishimoto, Nobuyuki Ishikura, H. Kawata, 2010, The Prostate.

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Miyuki Yoshida, Y. Aoki, O. Kondoh, 2011, Clinical Cancer Research.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

V. Seshan, S. Larson, N. Rosen, 2016, The Journal of clinical investigation.

[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

S. Stone-Elander, P. Pisa, J. Tessier, 2013, EJNMMI Research.

Cancer Therapy : Preclinical The Selective Class I PI 3 K Inhibitor CH 5132799 Targets Human Cancers Harboring Oncogenic PIK 3 CA Mutations

Miyuki Yoshida, N. Ishii, Y. Aoki, 2011 .

Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

M. Ohmori, Hiroki Nishii, K. Morikami, 2016, Journal of medicinal chemistry.

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1

M. Aoki, N. Ishii, T. Tsukaguchi, 2015, Molecular Cancer Therapeutics.

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

A. Iafrate, K. Flaherty, J. Baselga, 2019, Clinical Cancer Research.

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor

M. Aoki, N. Ishii, Y. Aoki, 2015, Molecular Cancer Therapeutics.

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers

Shigeo Sato, N. Ishii, Y. Aoki, 2012, Cancer science.

Isolation and characterization of Candida albicans homologue of RAP1, a repressor and activator protein gene in Saccharomyces cerevisiae.

R. Haw, H. Uemura, N. Ishii, 2004, Yeast.